Loretta J Nastoupil MD

PubMed

• Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.
  Dai Chihara, Raphael E Steiner, Ranjit Nair, Lei Feng, Sairah Ahmed
  Blood Advances. 2025-04-08
• Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
  Samuel Yamshon, Jean L Koff, Melissa C Larson, Brad S Kahl, Carla Casulo
  American Journal of Hematology. 2025-04-01
• Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
  Loretta J Nastoupil, Clark R Andersen, Amy Ayers, Yucai Wang, Thomas M Habermann
  Clinical Lymphoma, Myeloma & Leukemia. 2025-04-01

Journal Articles

• Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy  
  Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open
• Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy  
  Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
• Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding Study  
  N Fowler, E Reid, L J Nastoupil, Annals of Oncology

Abstracts/Posters

• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Follicular Lymphoma: Have We Made Progress? 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Follicular Lymphoma: Have We Made Progress? 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PI3Ks: The Next Generation 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Checkpoint Inhibitors in Lymphoma: When and How 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Join now to see all